23 Selvom disse bivirkninger menes at være relateret til disse stoffers ergoline struktur, vides det ikke, om andre non- ergoline dopaminagonister kan forårsage dem.
24 Although these adverse reactions are believed to be related to the ergoline structure of these compounds, whether other, nonergot derived dopamine agonists can cause them is unknown.